Daclatasvir + asunaprevir combination regimen - Bristol-Myers Squibb

Drug Profile

Daclatasvir + asunaprevir combination regimen - Bristol-Myers Squibb

Alternative Names: Asunaprevir + daclatasvir; BMS-650032 + BMS-790052; BMS-790052 + BMS-650032; Daklinza + Sunvepra; DCV Dual Regimen (daclatasvir and asunaprevir combination therapy); DCV+ASV Dual Regimen

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Antivirals; Biphenyl compounds; Carbamates; Cyclopropanes; Imidazoles; Isoquinolines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 28 Apr 2017 Registered for Hepatitis C (Treatment-naive) in China (PO)
  • 28 Apr 2017 Registered for Hepatitis C in China (PO)
  • 24 Apr 2017 Efficacy and safety data from the phase III Study 036 in Hepatitis C released by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top